Literature DB >> 2456068

Anagrelide: a potent and selective inhibitor of platelet cyclic AMP phosphodiesterase enzyme activity.

E Gillespie1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1988        PMID： 2456068     DOI： 10.1016/0006-2952(88)90054-8

Source DB:  PubMed          Journal:  Biochem Pharmacol        ISSN： 0006-2952            Impact factor:   5.858


× No keyword cloud information.
  6 in total

1.  Comparison of the biological activities of anagrelide and its major metabolites in haematopoietic cell cultures.

Authors:  Guosu Wang; Richard Franklin; Ying Hong; Jorge D Erusalimsky
Journal:  Br J Pharmacol       Date:  2005-10       Impact factor: 8.739

2.  Suppressive effects of anagrelide on cell cycle progression and the maturation of megakaryocyte progenitor cell lines in human induced pluripotent stem cells.

Authors:  Koji Takaishi; Masahiro Takeuchi; Shokichi Tsukamoto; Naoya Takayama; Motohiko Oshima; Kenji Kimura; Yusuke Isshiki; Kensuke Kayamori; Yutaro Hino; Nagisa Oshima-Hasegawa; Shio Mitsukawa; Yusuke Takeda; Naoya Mimura; Chikako Ohwada; Tohru Iseki; Sou Nakamura; Koji Eto; Atsushi Iwama; Koutaro Yokote; Chiaki Nakaseko; Emiko Sakaida
Journal:  Haematologica       Date:  2019-09-05       Impact factor: 9.941

Review 3.  Anagrelide. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in the treatment of thrombocythaemia.

Authors:  C M Spencer; R N Brogden
Journal:  Drugs       Date:  1994-05       Impact factor: 9.546

4.  EZH2 mutations and impact on clinical outcome: an analysis in 1,604 patients with newly diagnosed acute myeloid leukemia.

Authors:  Sebastian Stasik; Jan M Middeke; Michael Kramer; Christoph Röllig; Alwin Krämer; Sebastian Scholl; Andreas Hochhaus; Martina Crysandt; Tim H Brümmendorf; Ralph Naumann; Björn Steffen; Volker Kunzmann; Hermann Einsele; Markus Schaich; Andreas Burchert; Andreas Neubauer; Kerstin Schäfer-Eckart; Christoph Schliemann; Stefan Krause; Regina Herbst; Mathias Hänel; Norbert Frickhofen; Richard Noppeney; Ulrich Kaiser; Claudia D Baldus; Martin Kaufmann; Zdenek Rácil; Uwe Platzbecker; Wolfgang E Berdel; Jiri Mayer; Hubert Serve; Carsten Müller-Tidow; Gerhard Ehninger; Martin Bornhäuser; Johannes Schetelig; Christian Thiede
Journal:  Haematologica       Date:  2019-08-14       Impact factor: 9.941

Review 5.  The Use of Anagrelide in Myeloproliferative Neoplasms, with Focus on Essential Thrombocythemia.

Authors:  Gunnar Birgegård
Journal:  Curr Hematol Malig Rep       Date:  2016-10       Impact factor: 3.952

Review 6.  Headache in essential thrombocythaemia.

Authors:  R Frewin; A Dowson
Journal:  Int J Clin Pract       Date:  2012-08-14       Impact factor: 2.503
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.